An all-oral regimen extends control after CDK4/6 inhibition in breast cancer

Design

Phase 3, open-label, randomised trial (evERA)

Population

373 patients with ER-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor

Primary outcome

Investigator-assessed progression-free survival

Effect

Overall 8.8 vs 5.5 months (HR 0.56); ESR1-mutated 10.0 vs 5.5 months (HR 0.38)

Patients with ER-positive, HER2-negative advanced breast cancer who progress after a CDK4/6 inhibitor plus endocrine therapy need a better next line. The phase 3 evERA trial randomised 373 such patients to an all-oral regimen of the oral SERD giredestrant plus everolimus, or standard endocrine therapy (exemestane, fulvestrant or tamoxifen) plus everolimus.

Progression-free survival was longer with giredestrant–everolimus: 8.8 versus 5.5 months overall (hazard ratio 0.56), and the effect was concentrated in the 207 patients with ESR1-mutated tumours (10.0 vs 5.5 months, hazard ratio 0.38). Adverse events were similar between groups, with stomatitis, diarrhoea and anaemia the commonest.

The practice point is a new, fully oral option after CDK4/6 failure, strongest in ESR1-mutated disease — which is exactly the setting where endocrine resistance is often driven by ESR1 mutation. ESR1 testing at progression identifies who stands to gain most. Availability and cost will govern access in India, but the regimen's all-oral convenience suits outpatient care.

• Giredestrant–everolimus extended progression-free survival after CDK4/6-inhibitor failure in ER-positive breast cancer.
• The benefit was largest in ESR1-mutated tumours (10.0 vs 5.5 months, hazard ratio 0.38).
• The regimen is fully oral, with toxicity similar to standard endocrine therapy plus everolimus.
• Test for ESR1 mutation at progression to identify who benefits most.

Why it matters

It offers a new, convenient oral next line for a common resistance setting and ties the choice to an actionable biomarker.

Don't overread it

The benefit was concentrated in ESR1-mutated tumours and the endpoint was progression-free, not overall, survival in an open-label trial — the overall-population gain is modest.

The statistics, in plain English

A hazard ratio of 0.38 in ESR1-mutated disease is a large effect with a tight interval, but the overall-population 0.56 shows much of the benefit sits in that subgroup; progression-free survival is not yet shown to translate into longer life.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.